Last reviewed · How we verify
Liposome Irinotecan
Liposome Irinotecan is a Small molecule drug developed by China Medical University, China. It is currently FDA-approved. Also known as: duoenyi.
At a glance
| Generic name | Liposome Irinotecan |
|---|---|
| Also known as | duoenyi |
| Sponsor | China Medical University, China |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (PHASE3)
- Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer (PHASE2)
- A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer (PHASE3)
- Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread (PHASE2)
- Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma (PHASE1, PHASE2)
- Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma (PHASE2)
- SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC (NA)
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liposome Irinotecan CI brief — competitive landscape report
- Liposome Irinotecan updates RSS · CI watch RSS
- China Medical University, China portfolio CI
Frequently asked questions about Liposome Irinotecan
What is Liposome Irinotecan?
Liposome Irinotecan is a Small molecule drug developed by China Medical University, China.
Who makes Liposome Irinotecan?
Liposome Irinotecan is developed and marketed by China Medical University, China (see full China Medical University, China pipeline at /company/china-medical-university-china).
Is Liposome Irinotecan also known as anything else?
Liposome Irinotecan is also known as duoenyi.
What development phase is Liposome Irinotecan in?
Liposome Irinotecan is FDA-approved (marketed).
Related
- Manufacturer: China Medical University, China — full pipeline
- Also known as: duoenyi
- Compare: Liposome Irinotecan vs similar drugs
- Pricing: Liposome Irinotecan cost, discount & access